Baird Downgrades Tandem Diabetes Care (TNDM) to Neutral
- Dow, S&P hit highs; Trump comment hammers drug stocks
- Unusual 11 Mid-Day Movers 12/7: (ANTH) (EMKR) (PLAY) Higher; (SIGM) (OHAI) (FTK) Lower
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Western Digital (WDC) Raises Q2 Outlook
- Biotech, Pharma Stocks Weaker Amid Trump Comments on Lower Drug Prices
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Baird downgraded Tandem Diabetes Care (NASDAQ: TNDM) from Outperform to Neutral with a price target of $4.00 (from $11.00).
Shares of Tandem Diabetes Care closed at $5.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
- UPDATE: Stifel Downgrades Coca-Cola European Partners (CCE) to Hold
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!